H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the shares after the company announced Phase 2b topline data from the trial evaluating rosnilimab for treatment of rheumatoid arthritis. While the efficacy data is promising on week 14 results, some questions remain given the high placebo response and large bump at week 14 on responses, the analyst tells investors in a research note. However, the firm believes the safety and translational data support a favorable profile for rosnilimab. H.C. Wainwright updated AnaptysBio’s model to include $75M in milestones from GSK to the company in 2026 for $1B in annual sales of Jemperli. In addition, it increased estimates for collaboration revenues related to royalties from Jemperli and also recently imsidolimab.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data
- AnaptysBio Announces Promising Phase 2b RENOIR Trial Results
- AnaptysBio announces Phase 2b RENOIR trial met primary endpoint
- AnaptysBio’s Strong Financial Prospects Driven by Jemperli’s Growth and Strategic Partnerships
- Hold Rating for AnaptysBio: Strategic Licensing Decision Amid Limited GPP Market and Competitive Challenges
Questions or Comments about the article? Write to editor@tipranks.com